Gonadorelin injection 100mcg/vial
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Powder for solution for injection containing gonadorelin 100micrograms/vial.
Evaluating gonadotropic pituitary function following surgery/irradiation
Hypopituitarism (anterior pituitary function assessment)
Gonadorelin as a single injection is indicated for evaluating the functional capacity and response of the gonadotropes of the anterior pituitary. The LH/FSH-RH response is used in testing patients with suspected gonadotropin deficiency, whether due to the hypothalamus alone or in combination with anterior pituitary failure.
Gonadorelin is also indicated for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumour or surgery and/or irradiation.
100 micrograms injected subcutaneously or intravenously.
In females for whom the phase of the menstrual cycle can be established, the test should be performed in early follicular phase (days 1 to 7).
Children aged 1 to 18 years
2.5 micrograms/kg (up to 100 micrograms) as a single dose, injected subcutaneously or intravenously.
Additional Dosage Information
Refer to product information regarding specific methodology and interpretation of test results to determine the status of the gonadotropin secretory capacity of the anterior pituitary gland.
For subcutaneous and intravenous administration.
Children under 1 year
Precautions and Warnings
Exclude pregnancy prior to initiation of treatment
Female: Ensure adequate contraception during treatment
Ensure adequate contraception during treatment if administered during follicular phase of normal cycle, due to possible premature ovulation.
Rare instances of hypersensitivity reactions have been reported. Therefore, if intravenous re-administration is considered in patients treated by intermittent pulsatile therapy, they should be carefully observed.
The Norwegian Porphyria Centre (NAPOS) and the Porphyria centre Sweden, classifies gonadorelin as possibly porphyrinogenic. It should be used only when no safer alternative is available and precautions should be considered in vulnerable patients.
Not recommended for use in patients with pituitary adenoma as haemorrhagic infarction (pituitary apoplexy) may occur.
Pregnancy and Lactation
Gonadorelin is contraindicated during pregnancy.
At the time of writing, there is limited published information regarding the use of gonadorelin during pregnancy.
Gonadorelin is contraindicated during breastfeeding.
At the time of writing, there is limited published information regarding the use of gonadorelin during breastfeeding.
Localised and generalised rash
Menstrual bleeding increased
Redness of face, eyelids & lips
Thrombophlebitis (injection site)
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: December 2018
Summary of Product Characteristics: Gonadorelin 100 micrograms powder and solvent for solution for injection. Intrapharm Laboratories Ltd. May 2016.
NAPOS. The drug database for acute porphyria.
Available at: https://www.drugs-porphyria.org/
Pituitary and hypothalamic hormones and analogues. Last revised: September 2018.
Last accessed: 12 December 2018.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 12 December 2018.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.